Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

August 31, 2013

Study Completion Date

September 30, 2013

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG

bendamustine

120 mg/m2 IV, Days 1, 2 of Cycles 1-6

DRUG

rituximab

375 mg/m2 IV, Day 1 of Cycles 1-6

Trial Locations (33)

10467

Pharmatech Oncology Study Site, The Bronx

11706

Pharmatech Oncology Study Site, Bay Shore

11733

Pharmatech Oncology Study Site, East Setauket

17325

Pharmatech Oncology Study Site, Gettysburg

18015

Pharmatech Oncology Study Site, Bethlehem

20037

Pharmatech Oncology Study Site, Washington D.C.

20422

Pharmatech Oncology Study Site, Washington D.C.

29926

Pharmatech Oncology Study Site, Hilton Head

32605

Pharmatech Oncology Study Site, Gainesville

32796

Pharmatech Oncology Study Site, Titusville

33435

Pharmatech Oncology Study Site, Boynton Beach

34613

Pharmatech Oncology Study Site, Brooksville

38138

Pharmatech Oncology Study Site, Germantown

39202

Pharmatech Oncology Study Site, Jackson

42001

Pharmatech Oncology Study Site, Paducah

43219

Pharmatech Oncology Study Site, Columbus

44304

Pharmatech Oncology Study Site, Akron

47303

Pharmatech Oncology Study Site, Muncie

47904

Pharmatech Oncology Study Site, Lafayette

52001

Pharmatech Oncology Study Site, Dubuque

60435

Pharmatech Oncology Study Site, Joliet

63017

Pharmatech Oncology Study Site, Chesterfield

75080

Pharmatech Oncology Study Site, Richardson

76104

Pharmatech Oncology Study Site, Fort Worth

78463

Pharmatech Oncology Study Site, Corpus Christi

78759

Pharmatech Oncology Study Site, Austin

79410

Pharmatech Oncology Study Site, Lubbock

90211

Pharmatech Oncology Study Site, Beverly Hills

92708

Pharmatech Oncology Study Site, Fountain Valley

93030

Pharmatech Oncology Study Site, Oxnard

03909

Pharmatech Oncology Study Site, York Village

08003

Pharmatech Oncology Study Site, Cherry Hill

08865

Pharmatech Oncology Study Site, Phillipsburg

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Cephalon

INDUSTRY

lead

Pharmatech

INDUSTRY

NCT00831597 - Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter